Riskpilot← Back to searchSign inGet full accessOctapharma Nordic AB
ABActiveOrg 5566149794Elersvägen 40Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200136 employees
Revenue 2025
SEK 800,7M
-12% vs 2024
EBITDA margin
3.5%
-12% vs 2024
Equity ratio
99.0%
Financial strength
Net profit 2025
SEK 54,3M
-99% vs 2024
| Revenue | SEK 800,7M | -12% |
| EBITDA | SEK 28M | -12% |
| Net profit | SEK 54,3M | -99% |
| Total assets | SEK 2,8B | -35% |
| Equity | SEK 2,8B | -35% |
| Employees | 36 | — |
Legal name
Octapharma Nordic AB
Org number
5566149794
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28 augusti 2001
Share capital
SEK 1 299 000
Employees
36 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva handel med och förvaltning av värdepapper och handel med och marknadsföring av läkemedel, forskning och utveckling av läkemedel, samt idka därmed förenlig verksamhet.
Address
Elersvägen 40
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 990 015 | 1 471 448 | 109 349 | 908 447 | 800 726 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 34 646 | 51 505 | 3 827 | 31 799 | 28 028 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 34 646 | 51 505 | 3 827 | 31 799 | 28 028 |
| Net financials | 1 725 228 | 1 883 655 | 77 348 | 3 726 444 | 38 210 |
| Profit before tax | 1 759 864 | 1 935 149 | 81 175 | 3 758 220 | 66 228 |
| Tax | −2 932 | −11 055 | −960 | −11 677 | −11 947 |
| Net profit | 1 756 932 | 1 924 094 | 80 215 | 3 746 543 | 54 281 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 549 711 | 2 823 892 | 166 064 | 4 385 187 | 2 843 576 |
| Equity | 2 224 633 | 2 479 416 | 153 149 | 4 355 577 | 2 814 867 |
| Long-term debt | 293 907 | 318 895 | 8 673 | 0 | 0 |
| Short-term debt | 31 171 | 25 580 | 4 243 | 29 610 | 28 720 |
| Total debt | 325 078 | 344 475 | 12 916 | 29 610 | 28 720 |
EBITDA margin
3.5%
This company
15.8%
Market median
-78% vs market
20212025
Equity ratio
99.0%
This company
38.2%
Market median
+159% vs market
20212025
Return on equity
1.9%
This company
18.4%
Market median
-90% vs market
20212025
Net profit margin
6.8%
This company
8.1%
Market median
-16% vs market
20212025
Asset turnover
0.28×
This company
1.12×
Market median
-75% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TM Chief Executive Officer | Chief Executive Officer | 2020 |
ET Authorized Recipient of Service | Authorized Recipient of Service | 2020 |
ME Chief Auditor | Chief Auditor | 2021 |
| Former (1) | ||
KP Chief Auditor | Chief Auditor | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Octapharma Nordic AB (this company)
Ooo PiligrimOctapharma A/SOctapharma Biopharmaceuticals GmbhOctapharma South Africa (Pty) LtdOctapharma AgOOO PILIGRIMOCTAPHARMA BIOPHARMACEUTICALS GMBHOCTAPHARMA SOUTH AFRICA (PTY) LTDOCTAPHARMA A/SBoard members of Octapharma Nordic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Klas Patrik Israelsson | Chief Auditor | 0 companies |
| Tobias Marguerre | Chief Executive Officer | 0 companies |
| Erik Thomas Yngve Myrdal | Authorized Recipient of Service | 0 companies |
| Maria Elias | Chief Auditor | 0 companies |
| Wolfgang Hubert Marguerre | Chairman | 0 companies |
| Christina Abi Haidar | Board of Directors | 0 companies |
| Fredrik Marguerre | Board of Directors | 0 companies |